LCP
UTHR icon

Legacy Capital Partners’s United Therapeutics UTHR Stock Holding History

Legacy Capital Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-5,395
Closed -$602K – 115
2016
Q1 		$602K Sell
5,395
-2,955
-35% -$374K 0.39% 69
2015
Q4 		$1.31M Buy
8,350
+1,550
+23% +$226K 0.84% 44
2015
Q3 		$893K Hold
6,800
– – 0.61% 57
2015
Q2 		$1.18M Sell
6,800
-2,430
-26% -$437K 0.77% 47
2015
Q1 		$1.59M Sell
9,230
-1,375
-13% -$210K 1.01% 34
2014
Q4 		$1.37M Sell
10,605
-165
-2% -$21.3K 0.88% 42
2014
Q3 		$1.39M Sell
10,770
-350
-3% -$36.1K 0.92% 39
2014
Q2 		$985K Sell
11,120
-1,100
-9% -$106K 0.64% 54
2014
Q1 		$1.15M Sell
12,220
-6,165
-34% -$631K 0.81% 44
2013
Q4 		$2.08M Sell
18,385
-2,300
-11% -$207K 1.48% 23
2013
Q3 		$1.63M Sell
20,685
-320
-2% -$23.4K 1.22% 30
2013
Q2 		$1.38M Buy
+21,005
New +$1.35M 1.06% 35

Other funds holding UTHR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Legacy Capital Partners's UTHR Position: Q2 2016 in Review

Legacy Capital Partners sold out of United Therapeutics (UTHR) in Q2 2016, closing a stake of 5,395 shares — an estimated $602K sold.

Legacy Capital Partners first reported a position in UTHR in Q2 2013 and held it in 12 quarters. The position peaked at $2.08M in Q4 2013. 384 funds tracked by Wall St. Rank hold UTHR as of Q2 2016.

  • Legacy Capital Partners reported no remaining United Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Legacy Capital Partners sold 5,395 United Therapeutics shares in Q2 2016, an estimated $602K.
  • Legacy Capital Partners first reported a position in United Therapeutics in Q2 2013 and held it in 12 quarters.
  • Legacy Capital Partners's United Therapeutics position peaked at $2.08M in Q4 2013.
  • 384 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2016.

Based on Legacy Capital Partners's 13F filing for Q2 2016, filed 9 Aug 2016.